GB2154138A - Subcutaneous silicone implant - Google Patents

Subcutaneous silicone implant Download PDF

Info

Publication number
GB2154138A
GB2154138A GB08501731A GB8501731A GB2154138A GB 2154138 A GB2154138 A GB 2154138A GB 08501731 A GB08501731 A GB 08501731A GB 8501731 A GB8501731 A GB 8501731A GB 2154138 A GB2154138 A GB 2154138A
Authority
GB
United Kingdom
Prior art keywords
subcutaneous implant
implant according
subcutaneous
polymeric material
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB08501731A
Other versions
GB2154138B (en
GB8501731D0 (en
Inventor
James Francis Roche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drug Systems Res & Dev
Drug Systems Research And Development Ltd
Original Assignee
* DRUG SYSTEMS RESEARCH AND DEVELOPMENT LIMITED
DRUG SYSTEMS RES & DEV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IE34184A priority Critical patent/IE56979B1/en
Application filed by * DRUG SYSTEMS RESEARCH AND DEVELOPMENT LIMITED, DRUG SYSTEMS RES & DEV filed Critical * DRUG SYSTEMS RESEARCH AND DEVELOPMENT LIMITED
Publication of GB8501731D0 publication Critical patent/GB8501731D0/en
Publication of GB2154138A publication Critical patent/GB2154138A/en
Application granted granted Critical
Publication of GB2154138B publication Critical patent/GB2154138B/en
Application status is Expired legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61DVETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D7/00Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals

Abstract

A subcutaneous implant is provided for promoting growth in livestock and comprises a substantially hollow cylindrical component of silicone rubber, especially a dimethylpolysiloxane rubber, impregnated with a growth promoting amount of oestradiol. The implant has a core consisting of an active ingredient dispersed in a biocompatible, biosoluble polymeric material e.g. polyethylene glycol which dissolves within days of implantation. The active ingredient may be a drug, a hormone or a vaccine.

Description

SPECIFICATION Subcutaneous Implant This invention relates to subcutaneous implants and, in particular, to an oestradiol subcutaneous implant for use in promoting growth in livestock.

Subcutaneous oestradiol implants for the promotion of growth in ruminants are known. U.K. Patent Publication GB 2 030 044 A describes a solid, cylindrical subcutaneous implant for ruminants which has a biocompatible inert core and a biocompatible coating of oestradiol embedded in a dimethylpolysiloxane rubber. Release of oestradiol from the implant is determined by the surface area of the implant. With such an implant one observes a transitory increase in sexual activity in some of the implanted animals. However, this heightened sexual activity is generally only observed in about 2% of the animals.

It is also known that one can achieve a constant release of a steroid from silicone rubbers such as dimethylpolysiloxane (DPS) since the rubbers are readily permeable to steroids. Silicone rubbers such as DPS are found to be useful in implants because they do not cause foreign body reactions even after prolonged periods. After the implant has been exhausted, an empty hull of foreign material is left embedded in the tissue and can be removed and replaced by a fresh implant.

The administration of oestradiol to animals is considered to have two major effects. Firstly, it stimulates the release of growth hormone and secondly, recent work has indicated the presence of specific oestradiol receptors in muscle which results in oestradiol acting locally on muscle to stimulate growth. Furthermore, the administration of oestradiol bulls suppresses testicular development resulting in a reduced aggressiveness and easier farm management. Oestradiol administration effectively achieves a hormonal "castration" of male animals.

It is an object of the present invention to provide an improved subcutaneous implant for the sustained release of oestradiol and which includes means for ensuring a rapid release of a further active ingredient to an animal.

Accordingly, the invention provides a subcutaneous implantfor promoting growth in livestock, which comprises a substantially hollow cylindrical component of silicone rubber impregnated with a growth promoting amount of oestradiol, said component having a core consisting of an active ingredient dispersed in a biocompatible, biosoluble polymeric material which dissolves within days of implantation.

Preferably the livestock is represented by poultry or a ruminant animal.

Preferably, the oestradiol is present in the silicone rubber component at a concentration of from 1030% by weight, especially 20% by weight.

The silicone rubber is preferably a dimethylpolysiloxane (DPS) rubber. Especially preferred dimethylpolysiloxanes are those known generically as Silastic such as Silcoset sold by ICI plc or Silastic 382 and MDX-4-4210 sold by the Dow Corning Corporation. Such silicone rubbers consist of two components- a first component consisting of liquid, uncured rubber and a second component including a curing agent.

The first and second components are mixed and allowed to cure.

The biocompatible, biosoluble polymeric material defining the core of the implant is any biocompatible polymeric material which readily solu bilizes in vivo at body temperature and/or when it comes into contact with a body fluid.

A preferred polymeric material is polyethylene glycol. A preferred polyethylene glycol is one having a molecular weight in the range 3,00Q10,000, especial ly 4,000--5,000, in admixture with an equal portion of a polyethylene glycol having a molecular weight in the range 20S600, especially 300-400.

The active ingredient may be a drug, hormone or vaccine.

Suitable drugs include anthelmintics such as Levamisole or Ivermectin sold under the Trade Mark lvomec or other suitable water-soluble anthelmintic.

Suitable steroids include an anabolic steroid, progesterone or testosterone.

When the active ingredient is progesterone, one obtains an implant which is suitable for counteracting the transitory heightened sexual activity observed in certain animals when oestradiol only is administered by way of an implant.

Suitable vaccines include a black leg vaccine, an anti-clostridial vaccine sold under the Trade Mark Tribovax T or a salmonella vaccine sold under the Trade Mark Mellavax.

The core may also include a mixture of said active ingredients. The choice of active ingredient(s) is determined by the particular effect(s) which it is desired to elicit in an animal.

The dissolution time of the core is preferably 3 < days.

The implant is preferably 5--100 mm. in length, more especially 20--40 mm. The hollow cylindrical component preferably has a wall thickness of 0.1 to 2 mm, especially 1.0 mm. The diameter of the core is preferably 1 to 10 mm, especially 3 mm.

The invention also provides a method of promoting growth in livestock, which comprises implanting in an animal an implant as hereinabove described.

When the animal is a ruminant animal the implant is preferably implanted in the ear. It will be appreciated that the implant is desirably implanted in a portion of the body which is not destined for human consumption.

One method of manufacturing a subcutaneous implant as hereinabove described comprises the steps of: (a) centering a first tube in a second tube so as to leave a space therebetween corresponding to the desired wall thickness of the cylindrical component; (b) filling the space with a liquid silicone rubber containing oestradiol and allowing the silicone rubber to cure; and (c) removing the innertube and filling the resulting core with a filling quantity of active ingredient dispersed in a biocompatible, biosoluble polymeric material and causing the polymeric material to solidify.

The invention will be further illustrated by the following Examples EXAMPLE 1 Oestradiol (1 g.) (supplied by Sigma Limited, UK) was thoroughly mixed with (4 g.) component 1 of Medical Grade Silastic 382. Component 2 (0.05 g; 1%) of Silastic 382 (curing agent) was added and the materials were remixed and poured into a space 5 mm in thickness defined between a pair of centered tubes 120 mm in length. The oestradiol/silastic mixture was allowed to harden.

When the mixture had hardened the inner tube was removed. A mixture of progesterone (200 mg) in polyethylene glycol (M.W. 4.000) (159 mg) and polyethylene glycol (M.W. 300) (159 mg) was prepared and heated to 50"C. The mixture was poured into the core defined by the hardened silastic. The mixture was allowed to cool to room temperature and solidified. The outer tube was then removed and the implants were prepared therefrom by cutting into 30 mm lengths. The implants so formed are optionally sterilized in plastic packets.

EXAMPLE 2 Example 1 above was repeated exceptthatthe progesterone was replaced by Ivermectin in an amount sufficient to obtain an implant containing Ivermectin in a concentration of 20 mg per kg body weight.

Determination of Release Rate In vitro release rate was determined by incubating the implants for 24 hours at 370C with continuous shaking in Erlenmeyerflasks containing 30 mm 0.9% saline (Dziuk, P. J., and Cook, B. 1966 Endocrinology 78,208). The amount of oestradiol released into the medium was measured in a SP 800 Unicam Spectrophotometer at 280 nm following the extraction of oestradiol with methanol.

The in vivo release rate in the ear of heifers was estimated by measuring the fall in oestradiol concentration of the implant after it had been in the ear for known periods of time. After removal of the implant from the animals, the oestradiol was extracted by refluxing with methylene chloride for 24 hours.

After evaporation of the methyiene chloride with oxygen-free nitrogen, the oestradioi was then taken up in 2 1 of methanol. The concentration of oestradiol in the solution was determined in the spectrophotometer at 280 nm. No corrections were made for procedural losses but extraction of implants of known concentration indicated that recovery rates were over 90%.

Field Trials Field trials were carried out as follows: a group of animals (heifers or steers) were selected and randomised into two groups. One group of animals served as controls and the other group were implanted with subcutaneous implants prepared as in Example 1. The animals were weighed prior to implantation and at regular intervals (2-4 weeks) thereafter. The control animals were similarly weighed.

The results of these field trials are shown in Table 1.

TABLE 1 A. Steers-Trial 1 N (number Weight on Day of Initial Weight 196 Gain after animals) (kilos) (kilos) 196 days Control 5 285.0 459.2 174.2 Implant of 4 266.5 475.2 208.7 Example 1 B. Steers-Trial 2 N (number Weight on Day of Initial Weight 146 Gain after animals) (kilos) (kilos) 146 days Control 9 155.7 275.9 120.2 Implant of 9 153.9 285.3 131.4 Example 1 TABLE 1 (contd.) C. Heifers-Trial 3 N (number Weight on Day of Initial Weight 98 Gain after animals) (kilos) (kilos) 98 days Control 5 223.0 283.2 60.2 Implant of 5 208.8 291.6 82.8 Example 1 The results show in each case (Trials 1, 2 and 3) a significant increase in weight in the animals implanted with the subcutaneous implant of Example 1 over the period of the trial.

A trial (4) was also carried out to determine the daily liveweight gain of steers less than one year old, 150 days after implantation with oestradiol implants prepared according to Example 1. The results of this trial are given in Table 2.

TABLE 2 Daily live No. of Initial Wt. gain Treatment Steers Wt. (kg) (kg/day) Control 11 238 0.78 Implant of Example 1 10 214 1.00 (5 mmx30 mm) Another trial (5) was carried out to determine the daily liveweight gain of steers more than one year old, 150 days after implantation with oestradiol implants prepared according to Example 1. The results of this trial are given in Table 3.

TABLE 3 Daily live No. of Initial Wt. gain Treatment Steers Wt. (kg) (kg/day) Control 16 387 0.76 ImplantofExample1 18 367 1.10 (5 mmx30 mm) The steers subjected to trials (4) and (5) showed no abnormal behaviour. As indicated in Tables 2 and 3 significant increases in growth rate were observed.

Claims (31)

1. A subcutaneous implant for promoting growth in livestock, which comprises a substantially hollow cylindrical component of silicone rubber impregnated with a growth promoting amount of oestradiol, said component having a core consisting of an active ingredient dispersed in a biocompatible, biosoluble polymeric material which dissolves within days of implantation.
2. A subcutaneous implant according to Claim 1, wherein the oestradiol is present in the silicone rubber component art a concentration of from 1030% by weight.
3. A subcutaneous implant according to Claim 1 or 2, wherein the oestradiol is present in the silicone rubber component at a concentration of 20% by weight.
4. A subcutaneous implant according to any one of Claims 1 to 3, wherein the silicone rubber is a dimethylpolysiloxane rubber.
5. A subcutaneous implant according to any one of Claims 1 to 4, wherein the biocompatible, biosoluble polymeric material defining the core of the implant is any biocompatible polymeric material which readily solubilizes in vivo at body temperature and/or when it comes in contact with a body fluid.
6. A subcutaneous implant according to Claim 5, wherein the polymeric material is polyethylene glycol.
7. A subcutaneous implant according to Claim 6, wherein the polyethylene glycol polymeric material consists of a polyethylene glycol having a molecular weight in the range 3,000--10,000 in admixture with an equal portion of a polyethylene glycol having a molecular weight in the range 200--600.
8. A subcutaneous implant according to Claim 7, wherein the polyethylene glycol polymeric material consists of a polyethylene glycol having a molecular weight in the range 4,00-5,000, in admixture with an equal portion of a polyethylene glycol having a molecular weight in the range 300--400.
9. A subcutaneous implant according to any one of Claims 1 to 8, wherein the active ingredient is a drug, a hormone, a vaccine or a mixture thereof.
10. A subcutaneous implant according to Claim 9, wherein the drug is an anthelmintic.
11. A subcutaneous implant according to Claim 10, wherein the anthelmintic is Levamisole or Ivermectin.
12. A subcutaneous implant according to Claim 9, wherein the active ingredient is a steriod.
13. A subcutaneous implant according to Claim 12, wherein the steroid is an anabolic steroid.
14. A subcutaneous implant according to Claim 12, wherein the active ingredient is progesterone.
15. A subcutaneous implant according to Claim 12, wherein the active ingredient is testosterone.
16. A subcutaneous implant according to Claim 9, wherein the active ingredient is a vaccine selected from a black leg vaccine, an anti-clostridial vaccine or a salmonella vaccine.
17. A subcutaneous implant according to any preceding claim, which is 5--100 mm in length.
18. A subcutaneous implant according to Claim 17, which is 2040 mm in length.
19. A subcutaneous implant according to Claim 18, which is 30 mm in length.
20. A subcutaneous implant according to any preceding claim, wherein the hollow cylindrical component has a wall thickness of 0.1-2 mm.
21. A subcutaneous implant according to Claim 20, wherein the hollow cylindrical component has a wall thickness of 1 mm.
22. A subcutaneous implant according to any preceding claim, wherein the diameter of the core is between 1 and 10 mm.
23. A subcutaneous implant according to Claim 22, wherein the diameter of the core is 3 mm.
24. A method of manufacturing a subcutaneous implant according to any preceding claim, which comprises the steps of: (a) centering a first tube in a second tube so as to leave a space therebetween corresponding to the desired wall thickness of the cylindrical component; (b) filling the space with a liquid silicone rubber containing oestradiol and allowing the silicone rubber to cure; and (c) removing the innertube and filling the resulting core with a filling quantity of active ingredient dispersed in a biocompatible, biosoluble polymeric material and causing the polymeric material to solidify.
25. A method of promoting growth in livestock, which comprises implanting in an animal an implant as claimed in any one of Claims 1-23.
26. A method according to Claim 25, wherein the livestock is poultry.
27. A method according to Claim 25, wherein the livestock is a ruminant animal.
28. A subcutaneous implant according to Claim 1, substantially as hereinbefore described with particular reference to Examples 1 and 2 of the accompanying Examples.
29. A method according to Claim 25 of manufacturing a subcutaneous implant, substantially as hereinbefore described with particular reference to Examples 1 and 2 of the accompanying Examples.
30. A subcutaneous implant whenever manufactured by a method claimed in Claim 24 or 29.
31. A method according to Claim 25 for promoting growth in livestock, substantially as hereinbefore described with particular reference to the accompanying field trials.
GB08501731A 1984-02-14 1985-01-23 Subcutaneous silicone implant Expired GB2154138B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IE34184A IE56979B1 (en) 1984-02-14 1984-02-14 Subcutaneous implant

Publications (3)

Publication Number Publication Date
GB8501731D0 GB8501731D0 (en) 1985-02-27
GB2154138A true GB2154138A (en) 1985-09-04
GB2154138B GB2154138B (en) 1988-04-13

Family

ID=11010808

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08501731A Expired GB2154138B (en) 1984-02-14 1985-01-23 Subcutaneous silicone implant

Country Status (2)

Country Link
GB (1) GB2154138B (en)
IE (1) IE56979B1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006828A1 (en) * 1986-05-16 1987-11-19 The State Of Victoria Biocompatible implants
AU601443B2 (en) * 1986-05-16 1990-09-13 Monash Medical Centre Biocompatible implants
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
WO1999051201A1 (en) * 1998-04-03 1999-10-14 Ashmont Holdings Limited Sustained release formulation
WO2001043749A2 (en) * 1999-12-16 2001-06-21 Pharmacia & Upjohn Company Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
EP1424994A1 (en) * 2001-09-11 2004-06-09 Smart Drug Systems Inc. Preparation of sustained release pharmaceutical composition
KR100715748B1 (en) * 1999-12-16 2007-05-08 파마시아 앤드 업존 캄파니 엘엘씨 Pharmaceutical Implant Containing Immediate-Release and Sustained-Release Components and Method of Administration
WO2010144849A3 (en) * 2009-06-11 2011-02-03 Medtronic, Inc. Dissolvable pharmaceutical implant
GB2518944A (en) * 2013-10-05 2015-04-08 Ndm Technologies Ltd Solid dosage form
US10071104B2 (en) 2008-12-05 2018-09-11 Rebecca L. Glaser Pharmaceutical compositions containing testosterone and an aromatase inhibitor

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU601443B2 (en) * 1986-05-16 1990-09-13 Monash Medical Centre Biocompatible implants
WO1987006828A1 (en) * 1986-05-16 1987-11-19 The State Of Victoria Biocompatible implants
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US5756115A (en) * 1994-11-02 1998-05-26 The Population Coucil, Center For Biomedical Research Contraceptive method using a subdermally implantable device
WO1999051201A1 (en) * 1998-04-03 1999-10-14 Ashmont Holdings Limited Sustained release formulation
KR100715748B1 (en) * 1999-12-16 2007-05-08 파마시아 앤드 업존 캄파니 엘엘씨 Pharmaceutical Implant Containing Immediate-Release and Sustained-Release Components and Method of Administration
WO2001043749A2 (en) * 1999-12-16 2001-06-21 Pharmacia & Upjohn Company Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
WO2001043749A3 (en) * 1999-12-16 2002-01-03 Todd P Foster Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
EP1424994A4 (en) * 2001-09-11 2004-12-01 Smart Drug Systems Inc Preparation of sustained release pharmaceutical composition
EP1424994A1 (en) * 2001-09-11 2004-06-09 Smart Drug Systems Inc. Preparation of sustained release pharmaceutical composition
US10071104B2 (en) 2008-12-05 2018-09-11 Rebecca L. Glaser Pharmaceutical compositions containing testosterone and an aromatase inhibitor
WO2010144849A3 (en) * 2009-06-11 2011-02-03 Medtronic, Inc. Dissolvable pharmaceutical implant
GB2518944A (en) * 2013-10-05 2015-04-08 Ndm Technologies Ltd Solid dosage form

Also Published As

Publication number Publication date
IE56979B1 (en) 1992-02-26
GB2154138B (en) 1988-04-13
IE840341L (en) 1985-08-14
GB8501731D0 (en) 1985-02-27

Similar Documents

Publication Publication Date Title
US3545439A (en) Medicated devices and methods
US4725609A (en) Method of promoting healing
EP0537559B1 (en) Polymeric compositions useful as controlled release implants
US6126958A (en) Intravaginal rings with insertable drug-containing core
CA1333770C (en) Implantable, biodegradable system for releasing active substance
US5756115A (en) Contraceptive method using a subdermally implantable device
CN1212809C (en) Subcutaneous implant
US5429822A (en) Biodegradable bursting release system
JP3806197B2 (en) Intravaginal drug release device
US4589880A (en) Disposable spermicide-releasing diaphragm
EP0615438B1 (en) A carbohydrate glass matrix for the sustained release of a therapeutic agent
DE3034273C2 (en)
EP0246540B1 (en) Implant preparations for delivery of bioactive macromolecules
JP5868895B2 (en) Controlled release delivery of peptide or protein
US6444224B1 (en) Intra-vaginal device for pigs
EP0303306B1 (en) Contraceptive implant
EP1198236B1 (en) Bone graft substitute composition
AU777673B2 (en) Enhanced intra vaginal devices
FI102454B (en) Process for the treatment of erectile dysfunction, the compositions used in the preparation of I
JP2960098B2 (en) Chlorhexidine sustained release composition
US5614206A (en) Controlled dissolution pellet containing calcium sulfate
US4446578A (en) Joint treatment
US20090263441A1 (en) Drug depots having diffreent release profiles for reducing, preventing or treating pain and inflammation
EP0344090A2 (en) Synthetic resin matrix system incorporating healing enhancer
EP0478671B1 (en) Neurological therapy system

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19940123